DE4138042A1 - EPOTHILONES, THEIR PRODUCTION PROCESS AND MEANS CONTAINING THEM - Google Patents
EPOTHILONES, THEIR PRODUCTION PROCESS AND MEANS CONTAINING THEMInfo
- Publication number
- DE4138042A1 DE4138042A1 DE19914138042 DE4138042A DE4138042A1 DE 4138042 A1 DE4138042 A1 DE 4138042A1 DE 19914138042 DE19914138042 DE 19914138042 DE 4138042 A DE4138042 A DE 4138042A DE 4138042 A1 DE4138042 A1 DE 4138042A1
- Authority
- DE
- Germany
- Prior art keywords
- epothilones
- methanol
- merck
- epothilone
- strain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
- C12P17/181—Heterocyclic compounds containing oxygen atoms as the only ring heteroatoms in the condensed system, e.g. Salinomycin, Septamycin
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Health & Medical Sciences (AREA)
- Environmental Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Plant Pathology (AREA)
- Pest Control & Pesticides (AREA)
- Agronomy & Crop Science (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dentistry (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Die Erfindung betrifft Epothilone der folgenden allgemeinen Formel:The invention relates to epothilones of the following general formula:
worin R¹ Wasserstoff, C₁-C₄-Alkyl, C₁-C₄-Acyl, Li⁺, K⁺, Na⁺, 1/2 Mg2+ oder 1/2 Ca2+ bedeutet und R² Wasserstoff oder eine Methylgruppe darstellt.wherein R¹ is hydrogen, C₁-C₄-alkyl, C₁-C₄-acyl, Li⁺, K⁺, Na⁺, 1/2 Mg 2+ or 1/2 Ca 2+ and R² represents hydrogen or a methyl group.
Ferner betrifft die Erfindung eine Epothilon, gekennzeichnet durch einen oder mehrere der folgenden Parameter: The invention further relates to an epothilone, characterized by one or more of the following parameters:
C₂₆H₃₉NO₆S[493]
FAB-MS (neg. Ionen): 429.25 für (M-H)-
UV (MeOH) λmax (log ε) = 210 (4.17); 249 (3.97)C₂₆H₃₉NO₆S [493]
FAB-MS (neg. Ions): 429.25 for (MH) -
UV (MeOH) λ max (log ε) = 210 (4.17); 249 (3.97)
IR Film auf Irtran:
ν: 3429; 2966; 2937; 1737; 1691; 1463; 1374; 1295; 1257; 1185; 1150; 1087; 1029; 1014; 979 cm-1 IR film on Irtran:
ν: 3429; 2966; 2937; 1737; 1691; 1463; 1374; 1295; 1257; 1185; 1150; 1087; 1029; 1014; 979 cm -1
DC: RF = 0,75
DC-Alufolie 60 F₂₅₄, Merck; Laufmittel:
Dichlormethan/Methanol = 90 : 1
Detektion:
1. UV-Löschung bei 254 nm
2. Ansprühen mit Vanilin/Schwefelsäure-Reagenz und erhitzen auf 120°C, braune
AnfärbungDC: R F = 0.75
TLC aluminum foil 60 F₂₅₄, Merck; Eluent:
Dichloromethane / methanol = 90: 1
Detection:
1. UV quenching at 254 nm
2. Spray on with vanilin / sulfuric acid reagent and heat to 120 ° C, brown color
HPLC: Rt = 5,4 min
Säule: 4 × 250 mm Lichrosorb RP-18 7 µm, Merck;
Fluß: 1,5 ml/min; Laufmittel: Methanol/Wasser = 65 : 35
Detektor: UV 254 nmHPLC: R t = 5.4 min
Column: 4 × 250 mm Lichrosorb RP-18 7 µm, Merck;
Flow: 1.5 ml / min; Mobile solvent: methanol / water = 65:35
Detector: UV 254 nm
Des weiteren betrifft die Erfindung ein Epothilon, gekennzeichnet durch einen oder mehrere der folgenden Parameter: The invention further relates to an epothilone, characterized by one or more of the following parameters:
C₂₇H₄₁NO₆S[507]
FAB-MS (neg. Ionen): 506.25 für (M-H)-
UV (MeOH)λmax (log ε) = 210 (4.17); 249 (3.97)C₂₇H₄₁NO₆S [507]
FAB-MS (neg. Ions): 506.25 for (MH) -
UV (MeOH) λ max (log ε) = 210 (4.17); 249 (3.97)
IR Film auf Irtran:
ν = 3400; 2958; 2931; 2875; 1735; 1689; 1629; 1609; 1463; 1378; 1250; 1149; 1049; 977 cm-1 IR film on Irtran:
ν = 3400; 2958; 2931; 2875; 1735; 1689; 1629; 1609; 1463; 1378; 1250; 1149; 1049; 977 cm -1
DC: RF = 0,75
DC-Alufolie 60 F₂₅₄, Merck; Laufmittel:
Dichlormethan/Methanol = 90 : 10
Detektion:
1. UV-Löschung bei 254 nm
2. Ansprühen mit Vanilin/Schwefelsäure-Reagenz und erhitzt auf 120°C, braune AnfärbungDC: R F = 0.75
TLC aluminum foil 60 F₂₅₄, Merck; Eluent:
Dichloromethane / methanol = 90:10
Detection:
1. UV quenching at 254 nm
2. Spray on with vanilin / sulfuric acid reagent and heat to 120 ° C, brown color
HPLC: Rt = 6,3 min
Säule: 4 × 250 mm Lichrosorb RP-18 7 µm, Merck;
Fluß: 1,5 ml/min; Laufmittel: Methanol/Wasser = 65 : 35
Detektor: UV 254 nmHPLC: R t = 6.3 min
Column: 4 × 250 mm Lichrosorb RP-18 7 µm, Merck;
Flow: 1.5 ml / min; Mobile solvent: methanol / water = 65:35
Detector: UV 254 nm
Besonders bevorzugt sind Epothilone mit der folgenden StrukturformelEpothilones with the following structural formula are particularly preferred
worin R₂ Wasserstoff oder Methyl bedeutet. (Das Kohlenstoffatom der Methylgruppe wird als C27 bezeichnet). Ferner betrifft die Erfindung ein Verfahren zum Gewinnen von Epothilonen, insbesondere der vorstehend charakterisierten Epothilone, das dadurch gekennzeichnet ist, daß man den Stamm So ce90 DSM 6773wherein R₂ is hydrogen or methyl. (The carbon atom the methyl group is referred to as C27). Furthermore, the Invention a method for obtaining epothilones, in particular of the epothilones characterized above, which thereby is characterized in that the strain So ce90 DSM 6773
- - in einem Kohlenstoffquellen, Stickstoffquellen und Mineralsalze enthaltenden Medium kultiviert,- in a carbon sources, nitrogen sources and mineral salts cultivated medium,
- - entweder während der Kultivierung des Stammes oder anschließend ein Adsorberharz zusetzt,- either during the cultivation of the strain or afterwards adds an adsorber resin,
- - die Fermenterbrühe abtrennt,- separates the fermenter broth,
- - die Epothilone aus dem Adsorberharz eluiert und- the epothilones eluted from the adsorber resin and
- - die Eluate direkt oder über weitere Reinigungsschritte von dem/den Lösungsmittel(n) befreit,- the eluate directly or via further cleaning steps from freed from the solvent (s),
- - und gegebenenfalls über Hochdruck/Niederdruckchromatographie und/oder Umkristallisation die verschiedenen Epothilone aufreinigt und voneinander trennt.- And if necessary via high pressure / low pressure chromatography and / or recrystallization of the different epothilones purified and separated from each other.
Gegebenenfalls können die so gewonnenen Epothilone mit gängigen chemischen Verfahren weiter umgesetzt werden, z. B. mit Basen in die Alkali- und Erdalkalisalze überführt und gegebenenfalls weiter zu Ethern umgesetzt werden, oder sie können mit organischen Säuren in die entsprechenden Ester überführt werden.If necessary, the epothilones obtained in this way can be used with common chemical processes are further implemented, e.g. B. with bases in the alkali and alkaline earth metal salts are transferred and, if appropriate be further converted to ethers, or they can be organic Acids are converted into the corresponding esters.
Ferner betrifft die Erfindung ein Mittel für den Pflanzenschutz in Landwirtschaft, Forstwirtschaft und/oder Gartenbau, bestehend aus einem oder mehreren der vorstehend aufgeführten Epothilone oder eines oder mehrere dieser Epothilone enthaltend, gegebenenfalls neben einem oder mehreren üblichen Träger(n) und/oder Verdünnungsmittel(n). The invention further relates to an agent for crop protection in agriculture, forestry and / or horticulture from one or more of the epothilones listed above or containing one or more of these epothilones, if appropriate in addition to one or more conventional carriers and / or diluents.
Schließlich betrifft die Erfindung ein therapeutisches Mittel, das insbesondere cytotoxische Aktivitäten entwickeln und/oder Immunsupression bewirken kann, bestehend aus einem oder mehreren der vorstehend aufgeführten Epothilone oder eines oder mehrere dieser Epothilone enthaltend, gegebenenfalls neben einem oder mehreren üblichen Träger(n) und/oder Verdünnungsmittel(n).Finally, the invention relates to a therapeutic agent that develop cytotoxic activities in particular and / or Can cause immunosuppression consisting of one or more the epothilones listed above or one or more containing these epothilones, optionally next to one or several common carriers (s) and / or diluent (s).
Im folgenden wird die Erfindung anhand von Beispielen und experimentellen Daten näher erläutert.In the following the invention is illustrated by examples and experimental Data explained in more detail.
Stamm So ce90 wurde im Juli 1985 an der Gesellschaft für Biotechnologische Forschung (GBF) aus einer Bodenprobe von den Ufern des Zambesi, Südafrika, isoliert. Der Stamm ist bei der Deutschen Sammlung von Mikroorganismen (DSM) unter Nr. 6773 hinterlegt.Strain So ce90 was born in July 1985 at the Society for Biotechnological Research (GBF) a soil sample isolated from the banks of the Zambesi, South Africa. The tribe is with the German Collection of microorganisms (DSM) deposited under No. 6773.
Stammkultur und morphologische Beschreibung: Der Stamm wächst auf Cellulose als einziger Kohlenstoff- und Energiequelle mit KNO₃ als einzige Stickstoffquelle, z. B. auf Filterpapier über ST21 Mineralsalzagar (0.1% KNO₃; 0.1% MgSO₄ × 7 H₂O; 0.1% CaCl₂ × 2 H₂O; 0.1% K₂HPO₄; 0.01% MnSO₄ × 7 H₂O; 0.02% FeCl₃; 0.002% Hefeextrakt; Standard-Spurenelementlösung; 1% Agar). Auf diesem Medium werden dunkelrotbraune bis schwarzbraune Fruchtkörper gebildet, bestehend aus kleinen Sprangiolen (etwa 15 bis 30 µm Durchmesser) in mehr oder weniger großen dichten Haufen und Paketen.Strain culture and morphological description: The stem grows on cellulose as the only carbon and energy source with KNO₃ as the only nitrogen source, for. B. on filter paper over ST21 mineral salt agar (0.1% KNO₃; 0.1% MgSO₄ × 7 H₂O; 0.1% CaCl₂ × 2 H₂O; 0.1% K₂HPO₄; 0.01% MnSO₄ × 7 H₂O; 0.02% FeCl₃; 0.002% yeast extract; standard trace element solution; 1% agar). On this Medium dark red-brown to black-brown fruiting bodies are formed, consisting of small ones Sprangioles (about 15 to 30 µm in diameter) in more or less large dense piles and Packages.
Der Stamm wächst sehr gut mit Glucose und KNO₃, z. B. auf CA2-Agar (Grundmedium: 1.5 g Agar in 92 ml Aqua dest.; Stammlösung 1: 7.5% KNO₃, 7.5% K₂HPO₄ in Aqua dest,; Stammlösung 2: 1.5% MgSO₄ × 7 H₂O in Aqua dest.; Stammlösung 3: 0.2% CaCl₂ × 2 H₂O, 0.15% FeCl₃ in Aqua dest.; Stammlösung 4: 20% Glucose in Aqua dest. Die Stammlösungen werden durch Autoklavieren sterilisiert. Je 1 ml der Lösungen 1 bis 3, sowie 5 ml der Lösung 4 werden dem Grundmedium zugegeben, ebenso eine geeignete Menge einer Spurenelementlösung).The strain grows very well with glucose and KNO₃, e.g. B. on CA2 agar (basic medium: 1.5 g agar in 92 ml aqua dest .; Stock solution 1: 7.5% KNO₃, 7.5% K₂HPO₄ in distilled water ,; Stock solution 2: 1.5% MgSO₄ × 7 H₂O in aqua dest .; Stock solution 3: 0.2% CaCl₂ × 2 H₂O, 0.15% FeCl₃ in distilled water; Stock solution 4: 20% glucose in aqua dest. The stock solutions are made by autoclaving sterilized. 1 ml each of solutions 1 to 3 and 5 ml of solution 4 become the basic medium added, as well as a suitable amount of a trace element solution).
Die vegetativen Stäbchen haben für Sorangium typischen Form (relativ derbe, im Phasenkontrastmikroskop dunkle, zylindrische Stäbchen mit breit abgerundeten Enden, im Mittel 3-6 µm lang und 1 µm dick). Nach längerer Adaptation an das Wachstum in Flüssigmedien wächst der Stamm in homogener Zellsuspension. The vegetative rods have the typical shape of Sorangium (relatively coarse, in a phase contrast microscope dark, cylindrical rods with broadly rounded ends, on average 3-6 µm long and 1 µm thick). After a long adaptation to the growth in liquid media, the strain grows in homogeneous cell suspension.
Der Stamm So ce90 produziert chemisch nahe verwandte Verbindungen, die antibiotische Aktivität besitzen. Insbesondere sind diese Verbindungen cytotoxisch sowie antifungal wirksam. Hervorzuheben ist z. B. die Hemmung von Mucor hiemlis.The So ce90 strain produces chemically closely related compounds, which have antibiotic activity. In particular are these compounds are cytotoxic and antifungal. To emphasize is z. B. the inhibition of Mucor hiemlis.
Die Verbindungen werden während der logarithmischen bis hin zur stationären Wachstumsphase produziert.The connections are made during the logarithmic to the stationary growth phase produced.
Eine typische Fermentation verläuft folgendermaßen: Ein 100 l-Fermenter wird mit 60 l Medium (0.8% Stärke; 0.2% Glucose; 0.2% Soyamehl; 0.2% Hefeextrakt; 0.1% MgSO₄ × 7 H₂O; 8 mg/l Fe-EDTA; pH 7.4) gefüllt. Beimpft wird mit 10 l einer im gleichen Medium jedoch zusäztlich mit 50 mM HEPES-Puffer pH 7.4 in Schüttelkolben angezogenen Vorkultur (160 upm, 30°C). Fermentiert wird bei 32°C mit einer Rührgeschwindigkeit von 500 upm und einer Belüftung von 0.2 NL pro m³ und Std., der pH-Wert wird durch Zugabe von KOH bei 7.4 gehalten. Die Fermentation dauert 7-10 Tage . Die gebildeten aktiven Verbindungen befinden sich teils im Überstand und teils in den Zellen.A typical fermentation proceeds as follows: A 100 l fermenter is mixed with 60 l medium (0.8% Strength; 0.2% glucose; 0.2% soy flour; 0.2% yeast extract; 0.1% MgSO₄ × 7 H₂O; 8 mg / l Fe-EDTA; pH 7.4) filled. Inoculated with 10 l one in the same medium, however, in addition 50 mM HEPES buffer pH 7.4 in pre-culture (160 rpm, 30 ° C) grown in shake flasks. The fermentation takes place at 32 ° C with a stirring speed of 500 rpm and aeration of 0.2 NL per m³ and hour, the pH is kept at 7.4 by adding KOH. The fermentation lasts 7-10 days. The active compounds formed are partly in the supernatant and partly in the cells.
Alternativ dazu kann in Gegenwart von Adsorberharzen (z. B. XAD-1180, Rohm und Haas, 2-5%) fermentiert werden.Alternatively, in the presence of adsorber resins (e.g. XAD-1180, Rohm and Haas, 2-5%) be fermented.
Während der Fermentation von Sorangium cellulosum So ce90 (z. B. 70 l Fermentationsvolumen) in Gegenwart eines Adsorberharzes (z. B.: XAD-1180, Röhm und Haas, 2% v/v) werden die gebildeten Antibiotika Epothilon A (Abb. 1) und B (Abb. 2) vollständig an das Harz gebunden. Nach Abtrennung der Kulturbrühe (z. B. durch Absieben in einem Prozeßfilter) wird das Harz mit 3 Bettvolumen Wasser gewaschen und mit 4 Bettvolumen Methanol eluiert. Die vereinigten Eluate werden im Vakuum bis auf den Wassergehalt eingeengt und dreimal mit je 0,2 l Ethylacetat extrahiert. Die vereinigten Ethylacetatextrakte werden zur Trockne eingeengt (ca. 40 g Trockengewicht).During the fermentation of Sorangium cellulosum So ce90 (e.g. 70 l fermentation volume) in In the presence of an adsorber resin (e.g. XAD-1180, Röhm and Haas, 2% v / v) the formed Antibiotics Epothilon A (Fig. 1) and B (Fig. 2) fully bound to the resin. After separation the culture broth (e.g. by sieving in a process filter) the resin with 3 bed volumes of water washed and eluted with 4 bed volumes of methanol. The combined eluates are vacuumed up to the water content was concentrated and extracted three times with 0.2 l of ethyl acetate. The United Ethyl acetate extracts are evaporated to dryness (approx. 40 g dry weight).
Der Rohextrakt wird in 50 ml Methanol aufgenommen und an Lichroprep RP-18 25-40 µm (Säule: 400 × 100 mm; Fluß: 200 ml/min; Merck Prepbar) isokratisch mit Methanol/Wasser 6/4 chromatographiert. Die Epothilone enthaltenden Fraktionen (Rt ca. 95-125 min) werden durch RP-18 Niederdruckchromatographie aufgereinigt. (Säule 400 × 60; HD-Sil-18-20-60, Labomatic; Laufmittel: Methanol/Wasser 65/35; Fluß 25 ml/min; Rt Epothilon A: 140-165 min; Rt Epothilon B: 170-195 min.The crude extract is taken up in 50 ml of methanol and chromatographed isocratically with methanol / water 6/4 on Lichroprep RP-18 25-40 μm (column: 400 × 100 mm; flow: 200 ml / min; Merck Prepbar). The fractions containing epothilones (R t approx. 95-125 min) are purified by RP-18 low pressure chromatography. (400 × 60 column; HD-Sil-18-20-60, Labomatic; mobile solvent: methanol / water 65/35; flow 25 ml / min; R t epothilone A: 140-165 min; R t epothilone B: 170- 195 min.
Die Feinreinigung der Epothilone erfolgt durch Kristallisation ausThe epothilones are purified by crystallization
- 1. Epothilon A: Toluol/Ethylacetat = 3 : 21. Epothilon A: toluene / ethyl acetate = 3: 2
- 2. Epothilon B: Ethylacetat2. Epothilon B: ethyl acetate
Epothilon AEpothilone A
C₂₆H₃₉NO₆S[493]
FAB-MS (neg. Ionen): 429.25 für (M-H)-
¹H-NMR-Daten s. Tab. 1
¹³C-NMR-Daten s. Tab. 2
UV (MeOH) λmax (log ε) = 210 (4.17); 249 (3.97)
IR Film auf Irtran:
ν: 3429; 2966; 2937; 1737; 1691; 1463; 1374; 1295; 1257; 1185; 1150; 1087; 1029; 1014; 979 cm-1
DC: RF = 0,75
DC-Alufolie 60 F₂₅₄, Merck; Laufmittel:
Dichlormethan/Methanol = 90 : 10
Detektion: 1. UV-Löschung bei 254 nm
2. Ansprühen mit Vanillin/Schwefelsäure-Reagenz und erhitzen auf 120°C, braune
Anfärbung
HPLC: Rt = 5,4 min
Säule: 4 × 250 mm Lichrosorb RP-18 7 µm, Merck;
Fluß: 1,5 ml/min; Laufmittel: Methanol/Wasser = 65 : 35
Detektor: UV 254 nmC₂₆H₃₉NO₆S [493]
FAB-MS (neg. Ions): 429.25 for (MH) -
1 H-NMR data s. Tab. 1
13 C NMR data see. Tab. 2
UV (MeOH) λ max (log ε) = 210 (4.17); 249 (3.97)
IR film on Irtran:
ν: 3429; 2966; 2937; 1737; 1691; 1463; 1374; 1295; 1257; 1185; 1150; 1087; 1029; 1014; 979 cm -1
DC: R F = 0.75
TLC aluminum foil 60 F₂₅₄, Merck; Eluent:
Dichloromethane / methanol = 90:10
Detection: 1. UV quenching at 254 nm
2. Spray on with vanillin / sulfuric acid reagent and heat to 120 ° C, brown color
HPLC: R t = 5.4 min
Column: 4 × 250 mm Lichrosorb RP-18 7 µm, Merck;
Flow: 1.5 ml / min; Mobile solvent: methanol / water = 65:35
Detector: UV 254 nm
Epothilon BEpothilon B
C₂₇H₄₁NO₆S[507]
FAB-MS (neg. Ionen): 506.25 für (M-H)-
¹H-NMR-Daten s. Tab. 1
¹³C-NMR-Daten s. Tab. 2
UV (MeOH) λmax (log ε) = 210 (4.17); 249 (3.97)
IR Film auf Irtran:
ν = 3400; 2958; 2931; 2875; 1735; 1689; 1629; 1609; 1463; 1378; 1250; 1149; 1049; 977 cm-1
DC: RF = 0,75
DC-Alufolie 60 F₂₅₄, Merck; Laufmittel:
Dichlormethan/Methanol = 90 : 10
Detektion:
1. UV-Löschung bei 254 nm
2. Ansprühen mit Vanilin/Schwefelsäure-Reagenz und erhitzt auf 120°C, braune Anfärbung
HPLC: Rt = 6,3 min
Säule: 4 × 250 mm Lichrosorb RP-18 7 µm, Merck;
Fluß: 1,5 ml/min; Laufmittel: Methanol/Wasser = 65 : 35
Detektor: UV 254 nm
C₂₇H₄₁NO₆S [507]
FAB-MS (neg. Ions): 506.25 for (MH) -
1 H-NMR data s. Tab. 1
13 C NMR data see. Tab. 2
UV (MeOH) λ max (log ε) = 210 (4.17); 249 (3.97)
IR film on Irtran:
ν = 3400; 2958; 2931; 2875; 1735; 1689; 1629; 1609; 1463; 1378; 1250; 1149; 1049; 977 cm -1
DC: R F = 0.75
TLC aluminum foil 60 F₂₅₄, Merck; Eluent:
Dichloromethane / methanol = 90:10
Detection:
1. UV quenching at 254 nm
2. Spray on with vanilin / sulfuric acid reagent and heat to 120 ° C, brown color
HPLC: R t = 6.3 min
Column: 4 × 250 mm Lichrosorb RP-18 7 µm, Merck;
Flow: 1.5 ml / min; Mobile solvent: methanol / water = 65:35
Detector: UV 254 nm
Claims (8)
FAB-MS (neg. Ionen): 492.25 für (M-H)-
UV (MeOH) λmax (log ε) = 210 (4.17); 249 (3.97)IR Film auf Irtran:
ν: 3429; 2966; 2937; 1737; 1691; 1463; 1374; 1295; 1257; 1185; 1150; 1087; 1029; 1014; 979 cm-1
DC: RF = 0,75
DC-Alufolie 60 F₂₅₄, Merck; Laufmittel:
Dichlormethan/Methanol = 90 : 10
Detektion:
1. UV-Löschung bei 254 nm
2. Ansprühen mit Vanilin/Schwefelsäure-Reagenz und erhitzen auf 120°C, braune AnfärbungHPLC: Rt = 5,4 min
Säule: 4 × 250 mm Lichrosorb RP-18 7 µm, Merck;
Fluß: 1,5 ml/min; Laufmittel: Methanol/Wasser = 65 : 35
Detektor: UV 254 nm3. epothilone, characterized by one or more of the following parameters: C₂₆H₃₉NO₆S [493]
FAB-MS (neg. Ions): 492.25 for (MH) -
UV (MeOH) λ max (log ε) = 210 (4.17); 249 (3.97) IR film on Irtran:
ν: 3429; 2966; 2937; 1737; 1691; 1463; 1374; 1295; 1257; 1185; 1150; 1087; 1029; 1014; 979 cm -1
DC: R F = 0.75
TLC aluminum foil 60 F₂₅₄, Merck; Eluent:
Dichloromethane / methanol = 90:10
Detection:
1. UV quenching at 254 nm
2. Spray on with vanilin / sulfuric acid reagent and heat to 120 ° C, brown staining HPLC: R t = 5.4 min
Column: 4 × 250 mm Lichrosorb RP-18 7 µm, Merck;
Flow: 1.5 ml / min; Mobile solvent: methanol / water = 65:35
Detector: UV 254 nm
FAB-MS (neg. Ionen): 506.25 für (M-H)-
UV (MeOH)λmax (log ε) = 210 (4.17); 249 (3.97)IR Film auf Irtran:
ν = 3400; 2958; 2931; 2875; 1735; 1689; 1629; 1609; 1463; 1378; 1250; 1149; 1049; 977 cm-1DC: RF = 0,75
DC-Alufolie 60 F₂₅₄, Merck; Laufmittel:
Dichlormethan/Methanol = 90 : 10
Detektion:
1. UV-Löschung bei 254 nm
2. Ansprühen mit Vanilin/Schwefelsäure-Reagenz und erhitzt auf 120°C, braune AnfärbungHPLC: Rt = 6,3 min
Säule: 4 × 250 mm Lichrosorb RP-18 7 µm, Merck;
Fluß: 1,5 ml/min; Laufmittel: Methanol/Wasser = 65 : 35
Detektor: UV 254 nm4. epothilone, characterized by one or more of the following parameters: C₂₇H₄₁NO₆S [507]
FAB-MS (neg. Ions): 506.25 for (MH) -
UV (MeOH) λ max (log ε) = 210 (4.17); 249 (3.97) IR film on Irtran:
ν = 3400; 2958; 2931; 2875; 1735; 1689; 1629; 1609; 1463; 1378; 1250; 1149; 1049; 977 cm -1 DC: R F = 0.75
TLC aluminum foil 60 F₂₅₄, Merck; Eluent:
Dichloromethane / methanol = 90:10
Detection:
1. UV quenching at 254 nm
2. Spray on with vanilin / sulfuric acid reagent and heat to 120 ° C, brown staining HPLC: R t = 6.3 min
Column: 4 × 250 mm Lichrosorb RP-18 7 µm, Merck;
Flow: 1.5 ml / min; Mobile solvent: methanol / water = 65:35
Detector: UV 254 nm
- - in einem Kohlenstoffquellen, Stickstoffquellen und Mineralsalze enthaltenden Medium kultiviert,
- - entweder während der Kultivierung des Stammes oder anschließend ein Adsorberharz zusetzt,
- - die Fermenterbrühe abtrennt,
- - die Epothilone aus dem Adsorberharz eluiert und
- - die Eluate direkt oder über weitere Reinigungsschritte von dem/den Lösungsmittel(n) befreit,
- - und gegebenenfalls über Hochdruck/Niederdruckchromatographie und/oder Umkristallisation die verschiedenen Epothilone aufreinigt und voneinander trennt.
- - cultivated in a medium containing carbon sources, nitrogen sources and mineral salts,
- - either during the cultivation of the strain or subsequently adding an adsorber resin,
- - separates the fermenter broth,
- - the epothilones eluted from the adsorber resin and
- - the eluates are freed from the solvent (s) directly or through further cleaning steps,
- - and, if necessary, the various epothilones are purified and separated from one another by means of high pressure / low pressure chromatography and / or recrystallization.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19914138042 DE4138042C2 (en) | 1991-11-19 | 1991-11-19 | Epothilones, their production processes and agents containing these compounds |
PCT/EP1992/002656 WO1993010121A1 (en) | 1991-11-19 | 1992-11-19 | Epothilones, process for preparing the same and their use as medicaments and as plant protecting agents |
AU29437/92A AU2943792A (en) | 1991-11-19 | 1992-11-19 | Epothilones, process for preparing the same and their use as medicaments and as plant protecting agents |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19914138042 DE4138042C2 (en) | 1991-11-19 | 1991-11-19 | Epothilones, their production processes and agents containing these compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
DE4138042A1 true DE4138042A1 (en) | 1993-05-27 |
DE4138042C2 DE4138042C2 (en) | 1993-10-14 |
Family
ID=6445140
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE19914138042 Expired - Lifetime DE4138042C2 (en) | 1991-11-19 | 1991-11-19 | Epothilones, their production processes and agents containing these compounds |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU2943792A (en) |
DE (1) | DE4138042C2 (en) |
WO (1) | WO1993010121A1 (en) |
Cited By (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19636343C1 (en) * | 1996-08-30 | 1997-10-23 | Schering Ag | New (di:methyl)-dioxanyl-methyl-pentanone and related compounds |
WO1998022461A1 (en) * | 1996-11-18 | 1998-05-28 | GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) | Epothilone c, d, e and f, production process, and their use as cytostatic as well as phytosanitary agents |
WO1998038192A1 (en) * | 1997-02-25 | 1998-09-03 | GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) | Epothilones with a modified side chain |
WO1999007692A2 (en) * | 1997-08-09 | 1999-02-18 | Schering Aktiengesellschaft | New epothilone derivatives, method for producing same and their pharmaceutical use |
WO2000031247A2 (en) | 1998-11-20 | 2000-06-02 | Kosan Biosciences, Inc. | Recombinant methods and materials for producing epothilone and epothilone derivatives |
EP1019389A2 (en) * | 1997-07-08 | 2000-07-19 | Bristol-Myers Squibb Company | Epothilone derivatives |
EP1073647A1 (en) * | 1998-04-21 | 2001-02-07 | Bristol-Myers Squibb Company | 12,13-cyclopropane epothilone derivatives |
EP1073654A1 (en) * | 1998-04-21 | 2001-02-07 | Bristol-Myers Squibb Company | 2,3-olefinic epothilone derivatives |
US6194181B1 (en) | 1998-02-19 | 2001-02-27 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
US6262094B1 (en) | 1999-02-22 | 2001-07-17 | Bristol-Myers Squibb Company | C-21 modified epothilones |
US6288237B1 (en) | 1995-11-17 | 2001-09-11 | Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) | Epothilons C and D, preparation and compositions |
US6291684B1 (en) | 1999-03-29 | 2001-09-18 | Bristol-Myers Squibb Company | Process for the preparation of aziridinyl epothilones from oxiranyl epothilones |
US6302838B1 (en) | 1998-02-25 | 2001-10-16 | Novartis Ag | Cancer treatment with epothilones |
US6320045B1 (en) | 1997-12-04 | 2001-11-20 | Bristol-Myers Squibb Company | Process for the reduction of oxiranyl epothilones to olefinic epothilones |
US6365749B1 (en) | 1997-12-04 | 2002-04-02 | Bristol-Myers Squibb Company | Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs |
US6410301B1 (en) | 1998-11-20 | 2002-06-25 | Kosan Biosciences, Inc. | Myxococcus host cells for the production of epothilones |
US6441186B1 (en) * | 1996-12-13 | 2002-08-27 | The Scripps Research Institute | Epothilone analogs |
US6518421B1 (en) | 2000-03-20 | 2003-02-11 | Bristol-Myers Squibb Company | Process for the preparation of epothilone analogs |
US6531497B1 (en) | 1998-06-22 | 2003-03-11 | The Scripps Research Institute | Epothilone derivatives and their synthesis and use |
US6576651B2 (en) | 2001-01-25 | 2003-06-10 | Bristol-Myers Squibb Company | Pharmaceutical compositions, dosage forms and methods for oral administration of epothilones |
US6593115B2 (en) | 2000-03-24 | 2003-07-15 | Bristol-Myers Squibb Co. | Preparation of epothilone intermediates |
US6670384B2 (en) | 2001-01-25 | 2003-12-30 | Bristol-Myers Squibb Company | Methods of administering epothilone analogs for the treatment of cancer |
US6683100B2 (en) | 1999-01-19 | 2004-01-27 | Novartis Ag | Organic compounds |
US6686380B2 (en) | 2001-02-20 | 2004-02-03 | Bristol-Myers Squibb Company | Treatment of refractory tumors using epothilone derivatives |
US6689802B2 (en) | 2000-08-16 | 2004-02-10 | Bristol-Myers Squibb Company | Polymorphs of an epothilone analog |
US6727276B2 (en) | 2001-02-20 | 2004-04-27 | Bristol-Myers Squibb Company | Epothilone derivatives for the treatment of refractory tumors |
US6780620B1 (en) | 1998-12-23 | 2004-08-24 | Bristol-Myers Squibb Company | Microbial transformation method for the preparation of an epothilone |
US6800653B2 (en) | 2001-06-01 | 2004-10-05 | Bristol-Myers Squibb Compnay | Epothilone derivatives |
WO2004085388A2 (en) | 2003-03-24 | 2004-10-07 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
US6900160B2 (en) | 2000-09-22 | 2005-05-31 | Gesellschaft Fuer Biotechnologische Forschung Mbh | Triazolo-epothilones |
WO2005051947A1 (en) * | 2003-11-26 | 2005-06-09 | Leibniz-Institut Für Pflanzenbiochemie (Ipb) | Thiaepothilone for treating cancerous diseases |
US6936628B2 (en) | 2002-04-04 | 2005-08-30 | Bristol-Myers Squibb Company | Oral administration of epothilones |
WO2005084295A2 (en) | 2004-03-01 | 2005-09-15 | Bristol-Myers Squibb Company | Fused heterotricyclic compounds as inhibitors of 17b-hydroxysteroid dehydrogenase 3 |
US7001916B1 (en) | 1999-02-11 | 2006-02-21 | Schering, Ag | Epothilon derivatives, method for the production and the use thereof as pharmaceuticals |
US7008936B2 (en) | 2002-06-14 | 2006-03-07 | Bristol-Myers Squibb Company | Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases |
US7022330B2 (en) | 2001-01-25 | 2006-04-04 | Bristol-Myers Squibb Company | Parenteral formulation for epothilone analogs |
US7053069B2 (en) | 2002-05-15 | 2006-05-30 | Bristol-Myers Squibb Company | Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives |
US7091226B2 (en) | 1998-02-25 | 2006-08-15 | Novartis Ag | Cancer treatment with epothilones |
US7125893B1 (en) | 1999-04-30 | 2006-10-24 | Schering Ag | 6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations |
US7172884B2 (en) | 2002-09-23 | 2007-02-06 | Bristol-Myers Squibb Company | Methods for the preparation, isolation and purification of epothilone B, and x-ray crystal structures of epothilone B |
US7173137B2 (en) * | 1996-12-13 | 2007-02-06 | The Scripps Research Institute | Epothilone analogs |
US7211593B2 (en) | 2002-03-12 | 2007-05-01 | Bristol-Myers Squibb Co. | C12-cyano epothilone derivatives |
US7312237B2 (en) | 2001-03-14 | 2007-12-25 | Bristol-Myers Squibb Co. | Combination of epothilone analogs and chemotherapeutic agents for the treatment of prolilferative diseases |
EP2065054A1 (en) | 2007-11-29 | 2009-06-03 | Bayer Schering Pharma Aktiengesellschaft | Combinations comprising a prostaglandin and uses thereof |
EP2070521A1 (en) | 2007-12-10 | 2009-06-17 | Bayer Schering Pharma Aktiengesellschaft | Surface-modified nanoparticles |
US7632858B2 (en) | 2002-11-15 | 2009-12-15 | Bristol-Myers Squibb Company | Open chain prolyl urea-related modulators of androgen receptor function |
US7759374B2 (en) | 2002-08-23 | 2010-07-20 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
EP2210584A1 (en) | 2009-01-27 | 2010-07-28 | Bayer Schering Pharma Aktiengesellschaft | Stable polymeric composition comprising an epothilone and an amphiphilic block copolymer |
US7875638B2 (en) | 2002-08-23 | 2011-01-25 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
EP2308833A2 (en) | 1999-04-15 | 2011-04-13 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
US8017749B2 (en) | 2006-12-04 | 2011-09-13 | The Board Of Trustees Of The University Of Illinois | Compositions and methods to treat cancer with cupredoxins and CpG rich DNA |
WO2013041014A1 (en) | 2011-09-19 | 2013-03-28 | 北京市丰硕维康技术开发有限责任公司 | Platinum compound having amino- or alkylamino-containing succinic acid derivatives as leaving group, preparation method therefor, and use thereof |
WO2014075391A1 (en) | 2012-11-17 | 2014-05-22 | 北京市丰硕维康技术开发有限责任公司 | Platinum compound of malonic acid derivative having leaving group containing amino or alkylamino |
US8871227B2 (en) | 2003-11-04 | 2014-10-28 | Bristol-Myers Squibb Company | Process and formulation containing epothilones and analogs thereof |
US9138421B2 (en) | 2011-07-09 | 2015-09-22 | Beijing Fswelcome Technology Development Co., Ltd. | Platinum compounds for treating cell proliferative diseases, preparation method and use thereof |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6441025B2 (en) | 1996-03-12 | 2002-08-27 | Pg-Txl Company, L.P. | Water soluble paclitaxel derivatives |
US5969145A (en) * | 1996-08-30 | 1999-10-19 | Novartis Ag | Process for the production of epothilones and intermediate products within the process |
AU716610B2 (en) * | 1996-08-30 | 2000-03-02 | Novartis Ag | Method for producing epothilones, and intermediate products obtained during the production process |
US6204388B1 (en) | 1996-12-03 | 2001-03-20 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
JP4579351B2 (en) | 1996-12-03 | 2010-11-10 | スローン−ケッタリング インスティトュート フォア キャンサー リサーチ | Synthesis of epothilone and its intermediates and analogs and uses thereof |
JP4434484B2 (en) * | 1997-12-04 | 2010-03-17 | ブリストル−マイヤーズ スクイブ カンパニー | Reduction of oxiranyl epothilone compounds to olefinic epothilone compounds |
MY125921A (en) * | 1998-02-05 | 2006-08-30 | Novartis Ag | Compositions containing organic compounds |
GB9802451D0 (en) * | 1998-02-05 | 1998-04-01 | Ciba Geigy Ag | Organic compounds |
DE19820599A1 (en) | 1998-05-08 | 1999-11-11 | Biotechnolog Forschung Gmbh | New epothilone derivatives useful as pharmaceuticals and in plant protection |
US6121029A (en) | 1998-06-18 | 2000-09-19 | Novartis Ag | Genes for the biosynthesis of epothilones |
DE69804448T2 (en) * | 1998-08-05 | 2002-11-07 | Gesellschaft Fuer Biotechnologische Forschung Mbh (Gbf) | Pharmaceutical agents containing epothilone A N-oxide and / or epothilone B N-oxide |
DE19848306A1 (en) | 1998-10-14 | 2000-04-20 | Schering Ag | High yield preparation of cytotoxic or fungicidal compound epothilon B, from phenylsulfonyl-butanol derivative by multistage process via new thiazole derivative intermediates |
US6596875B2 (en) | 2000-02-07 | 2003-07-22 | James David White | Method for synthesizing epothilones and epothilone analogs |
GB0003753D0 (en) * | 2000-02-17 | 2000-04-05 | Biochemie Gmbh | Organic compounds |
US20020077290A1 (en) | 2000-03-17 | 2002-06-20 | Rama Bhatt | Polyglutamic acid-camptothecin conjugates and methods of preparation |
US6589968B2 (en) | 2001-02-13 | 2003-07-08 | Kosan Biosciences, Inc. | Epothilone compounds and methods for making and using the same |
GB0029895D0 (en) * | 2000-12-07 | 2001-01-24 | Novartis Ag | Organic compounds |
US6893859B2 (en) | 2001-02-13 | 2005-05-17 | Kosan Biosciences, Inc. | Epothilone derivatives and methods for making and using the same |
RU2313345C2 (en) | 2001-02-27 | 2007-12-27 | Новартис Аг | Combinations containing transduction signal inhibitor and epotilone derivative |
TWI315982B (en) | 2001-07-19 | 2009-10-21 | Novartis Ag | Combinations comprising epothilones and pharmaceutical uses thereof |
US6884608B2 (en) | 2001-12-26 | 2005-04-26 | Bristol-Myers Squibb Company | Compositions and methods for hydroxylating epothilones |
CA2471509A1 (en) | 2002-01-14 | 2003-07-17 | Novartis Ag | Combinations comprising epothilones and anti-metabolites |
DE60330651D1 (en) | 2002-03-12 | 2010-02-04 | Bristol Myers Squibb Co | C3-cyanoepothilonderivate |
DE10344882A1 (en) | 2003-09-26 | 2005-04-21 | Morphochem Ag Komb Chemie | New macrocycles for the treatment of cancer |
US20060121511A1 (en) | 2004-11-30 | 2006-06-08 | Hyerim Lee | Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents |
CN1312286C (en) * | 2005-10-19 | 2007-04-25 | 华南理工大学 | Method for highly-effective producing epothilone using myxobacteria sorangium cellulosum |
CA2647565A1 (en) | 2006-03-31 | 2007-10-18 | Bristol-Myers Squibb Company | Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents |
WO2008147941A1 (en) | 2007-05-25 | 2008-12-04 | Bristol-Myers Squibb Company | Processes for making epothilone compounds and analogs |
DE102007059752A1 (en) | 2007-12-10 | 2009-06-18 | Bayer Schering Pharma Aktiengesellschaft | Functionalized solid polymer nanoparticles containing epothilones |
JP5180321B2 (en) * | 2008-02-01 | 2013-04-10 | 浙江海正薬業股▲ふん▼有限公司 | Separation and purification method of epothilone |
CN101362784A (en) * | 2008-10-06 | 2009-02-11 | 山东大学 | Ebomycin glycosides compounds, composition using the same as activity component and use thereof |
EP2571525A4 (en) | 2010-05-18 | 2016-04-27 | Cerulean Pharma Inc | Compositions and methods for treatment of autoimmune and other diseases |
US8618146B2 (en) | 2011-01-03 | 2013-12-31 | Dr. Reddy's Laboratories Limited | Epothilone compound formulations |
CN103145722B (en) * | 2013-03-05 | 2015-12-02 | 福建省微生物研究所 | A kind of method of high speed adverse current chromatogram separating-purifying ebormycine |
US20160185793A1 (en) * | 2013-08-19 | 2016-06-30 | Sandoz Ag | Method for the purification of epothilones via crystallization |
-
1991
- 1991-11-19 DE DE19914138042 patent/DE4138042C2/en not_active Expired - Lifetime
-
1992
- 1992-11-19 AU AU29437/92A patent/AU2943792A/en not_active Abandoned
- 1992-11-19 WO PCT/EP1992/002656 patent/WO1993010121A1/en active Application Filing
Non-Patent Citations (1)
Title |
---|
NICHTS ERMITTELT * |
Cited By (121)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6288237B1 (en) | 1995-11-17 | 2001-09-11 | Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) | Epothilons C and D, preparation and compositions |
US6831076B2 (en) | 1995-11-17 | 2004-12-14 | Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) | Epothilons C and D, preparation and compositions |
US6613912B2 (en) | 1995-11-17 | 2003-09-02 | Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) | Epothilons C and D, preparation and compositions |
DE19636343C1 (en) * | 1996-08-30 | 1997-10-23 | Schering Ag | New (di:methyl)-dioxanyl-methyl-pentanone and related compounds |
WO1998022461A1 (en) * | 1996-11-18 | 1998-05-28 | GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) | Epothilone c, d, e and f, production process, and their use as cytostatic as well as phytosanitary agents |
US7846952B2 (en) | 1996-11-18 | 2010-12-07 | Helmholtz-Zentrum Fuer Infektionsforschung Gmbh | Epothilones C, D, E, and F, preparation and compositions |
US8076490B2 (en) | 1996-11-18 | 2011-12-13 | Helmholtz-Zentrum Fuer Infektionsforschung Gmbh | Epothilones C, D, E, and F, preparation and compositions |
EP1367057A1 (en) * | 1996-11-18 | 2003-12-03 | Gesellschaft für biotechnologische Forschung mbH (GBF) | Epothilones C, E and F |
US7173137B2 (en) * | 1996-12-13 | 2007-02-06 | The Scripps Research Institute | Epothilone analogs |
US6441186B1 (en) * | 1996-12-13 | 2002-08-27 | The Scripps Research Institute | Epothilone analogs |
WO1998038192A1 (en) * | 1997-02-25 | 1998-09-03 | GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) | Epothilones with a modified side chain |
USRE41895E1 (en) | 1997-07-08 | 2010-10-26 | Bristol-Myers Squibb Company | Epothilone derivatives |
US6605599B1 (en) | 1997-07-08 | 2003-08-12 | Bristol-Myers Squibb Company | Epothilone derivatives |
EP1526133A1 (en) * | 1997-07-08 | 2005-04-27 | Bristol-Myers Squibb Company | Epothilone derivatives |
EP1531153A1 (en) * | 1997-07-08 | 2005-05-18 | Bristol-Myers Squibb Company | Epothilone derivatives |
US7241755B2 (en) | 1997-07-08 | 2007-07-10 | Bristol-Myers Squibb Company | Epothilone derivatives |
EP1019389A4 (en) * | 1997-07-08 | 2001-11-07 | Bristol Myers Squibb Co | Epothilone derivatives |
US8536327B2 (en) | 1997-07-08 | 2013-09-17 | Bristol-Myers Squibb Company | Epothilone derivatives |
US8921542B2 (en) | 1997-07-08 | 2014-12-30 | Bristol-Myers Squibb Company | Epothilone derivatives |
CZ297904B6 (en) * | 1997-07-08 | 2007-04-25 | Bristol-Myers Squibb Company | Epothilone derivatives |
EP1493738A1 (en) * | 1997-07-08 | 2005-01-05 | Bristol-Myers Squibb Company | Epothilone derivatives |
USRE41911E1 (en) | 1997-07-08 | 2010-11-02 | Bristol-Myers Squibb Company | Epothilone derivatives |
US7125899B2 (en) | 1997-07-08 | 2006-10-24 | Bristol-Myers Squibb Company | Epothilone derivatives |
USRE43003E1 (en) | 1997-07-08 | 2011-12-06 | Bristol-Myers Squibb Company | Epothilone derivatives |
EP1019389A2 (en) * | 1997-07-08 | 2000-07-19 | Bristol-Myers Squibb Company | Epothilone derivatives |
USRE41893E1 (en) | 1997-07-08 | 2010-10-26 | Bristol-Myers Squibb Company | Epothilone derivatives |
WO1999007692A3 (en) * | 1997-08-09 | 1999-05-14 | Schering Ag | New epothilone derivatives, method for producing same and their pharmaceutical use |
WO1999007692A2 (en) * | 1997-08-09 | 1999-02-18 | Schering Aktiengesellschaft | New epothilone derivatives, method for producing same and their pharmaceutical use |
EP1847540A1 (en) * | 1997-08-09 | 2007-10-24 | Bayer Schering Pharma Aktiengesellschaft | Nouveaux dérivés d'épothilone, leur procédé de production et leur utilisation pharmaceutique |
US7407975B2 (en) | 1997-08-09 | 2008-08-05 | Bayer Schering Pharma Ag | Epothilone derivatives, method for producing same and their pharmaceutical use |
US6365749B1 (en) | 1997-12-04 | 2002-04-02 | Bristol-Myers Squibb Company | Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs |
US6320045B1 (en) | 1997-12-04 | 2001-11-20 | Bristol-Myers Squibb Company | Process for the reduction of oxiranyl epothilones to olefinic epothilones |
US7101702B2 (en) | 1998-02-19 | 2006-09-05 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
US6194181B1 (en) | 1998-02-19 | 2001-02-27 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
US6380227B1 (en) | 1998-02-19 | 2002-04-30 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
US6656711B2 (en) | 1998-02-19 | 2003-12-02 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
US7091226B2 (en) | 1998-02-25 | 2006-08-15 | Novartis Ag | Cancer treatment with epothilones |
US6302838B1 (en) | 1998-02-25 | 2001-10-16 | Novartis Ag | Cancer treatment with epothilones |
US7875601B2 (en) | 1998-02-25 | 2011-01-25 | Novartis Ag | Cancer treatment with epothilones |
EP1073648A4 (en) * | 1998-04-21 | 2003-01-02 | Bristol Myers Squibb Co | 12,13-modified epothilone derivatives |
EP1073647A1 (en) * | 1998-04-21 | 2001-02-07 | Bristol-Myers Squibb Company | 12,13-cyclopropane epothilone derivatives |
US6380395B1 (en) | 1998-04-21 | 2002-04-30 | Bristol-Myers Squibb Company | 12, 13-cyclopropane epothilone derivatives |
EP1073654A4 (en) * | 1998-04-21 | 2003-01-02 | Bristol Myers Squibb Co | 2,3-olefinic epothilone derivatives |
EP1073648A1 (en) * | 1998-04-21 | 2001-02-07 | Bristol-Myers Squibb Company | 12,13-Modified epothilone derivatives |
EP1073654A1 (en) * | 1998-04-21 | 2001-02-07 | Bristol-Myers Squibb Company | 2,3-olefinic epothilone derivatives |
US6831090B2 (en) | 1998-04-21 | 2004-12-14 | Bristol-Myers Squibb Company | 2,3-olefinic epothilone derivatives |
EP1589017A3 (en) * | 1998-04-21 | 2009-04-22 | Bristol-Myers Squibb Company | 12,13-modified epothilone derivatives |
US6399638B1 (en) | 1998-04-21 | 2002-06-04 | Bristol-Myers Squibb Company | 12,13-modified epothilone derivatives |
EP1073647A4 (en) * | 1998-04-21 | 2003-01-02 | Bristol Myers Squibb Co | 12,13-cyclopropane epothilone derivatives |
US6498257B1 (en) | 1998-04-21 | 2002-12-24 | Bristol-Myers Squibb Company | 2,3-olefinic epothilone derivatives |
US6531497B1 (en) | 1998-06-22 | 2003-03-11 | The Scripps Research Institute | Epothilone derivatives and their synthesis and use |
US7579366B2 (en) | 1998-06-22 | 2009-08-25 | The Scripps Research Institute | Epothilone derivatives and their synthesis and use |
US6583290B1 (en) | 1998-11-20 | 2003-06-24 | Kosam Biosciences, Inc. | 14-methyl epothilone derivatives |
WO2000031247A2 (en) | 1998-11-20 | 2000-06-02 | Kosan Biosciences, Inc. | Recombinant methods and materials for producing epothilone and epothilone derivatives |
US6858411B1 (en) | 1998-11-20 | 2005-02-22 | Kosan Biosciences, Inc. | Recombinant methods and materials for producing epothilone and epothilone derivatives |
US6303342B1 (en) | 1998-11-20 | 2001-10-16 | Kason Biosciences, Inc. | Recombinant methods and materials for producing epothilones C and D |
US6410301B1 (en) | 1998-11-20 | 2002-06-25 | Kosan Biosciences, Inc. | Myxococcus host cells for the production of epothilones |
US6921650B1 (en) | 1998-11-20 | 2005-07-26 | Kosan Biosciences, Inc. | Recombinant methods and materials for producing epothilone and epothilone derivatives |
US7402421B2 (en) | 1998-11-20 | 2008-07-22 | Kosan Biosciences, Inc. | Recombinant methods and materials for producing epothilone and epothilone derivatives |
US7067286B2 (en) | 1998-11-20 | 2006-06-27 | Kosan Biosciences, Inc. | Cystobacterineae host cells containing heterologous PKS genes for the synthesis of polykedtides |
US7732186B2 (en) | 1998-11-20 | 2010-06-08 | Kosan Biosciences, Inc. | Recombinant methods and materials for producing epothilone and epothilone derivatives |
US7129071B1 (en) | 1998-11-20 | 2006-10-31 | Kosan Biosciences, Inc. | Recombinant methods and materials for producing epothilone and epothilone derivatives |
US6780620B1 (en) | 1998-12-23 | 2004-08-24 | Bristol-Myers Squibb Company | Microbial transformation method for the preparation of an epothilone |
US7244594B2 (en) | 1998-12-23 | 2007-07-17 | Bristol-Myers Squibb Company | Microbial transformation method for the preparation of an epothilone |
US6683100B2 (en) | 1999-01-19 | 2004-01-27 | Novartis Ag | Organic compounds |
US7001916B1 (en) | 1999-02-11 | 2006-02-21 | Schering, Ag | Epothilon derivatives, method for the production and the use thereof as pharmaceuticals |
US6262094B1 (en) | 1999-02-22 | 2001-07-17 | Bristol-Myers Squibb Company | C-21 modified epothilones |
US6291684B1 (en) | 1999-03-29 | 2001-09-18 | Bristol-Myers Squibb Company | Process for the preparation of aziridinyl epothilones from oxiranyl epothilones |
EP3222619A1 (en) | 1999-04-15 | 2017-09-27 | Bristol-Myers Squibb Holdings Ireland | Cyclic protein tyrosine kinase inhibitors |
EP2308833A2 (en) | 1999-04-15 | 2011-04-13 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
US7125893B1 (en) | 1999-04-30 | 2006-10-24 | Schering Ag | 6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations |
US7700621B2 (en) | 1999-04-30 | 2010-04-20 | Bayer Schering Pharma Aktiengesellschaft | 6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations |
USRE39356E1 (en) * | 2000-03-20 | 2006-10-17 | Bristol-Myers Squibb Co. | Process for the preparation of epothilone analogs |
US6518421B1 (en) | 2000-03-20 | 2003-02-11 | Bristol-Myers Squibb Company | Process for the preparation of epothilone analogs |
US6593115B2 (en) | 2000-03-24 | 2003-07-15 | Bristol-Myers Squibb Co. | Preparation of epothilone intermediates |
US7153879B2 (en) | 2000-08-16 | 2006-12-26 | Bristol-Myers Squibb Company | Polymorphs of an epothilone analog |
US6982276B2 (en) | 2000-08-16 | 2006-01-03 | Bristol-Myers Squibb Company | Polymorphs of an epothilone analog |
US6689802B2 (en) | 2000-08-16 | 2004-02-10 | Bristol-Myers Squibb Company | Polymorphs of an epothilone analog |
USRE39251E1 (en) * | 2000-08-16 | 2006-08-29 | Bristol-Myers Squibb Co. | Polymorphs of an epothilone analog |
US6900160B2 (en) | 2000-09-22 | 2005-05-31 | Gesellschaft Fuer Biotechnologische Forschung Mbh | Triazolo-epothilones |
US7022330B2 (en) | 2001-01-25 | 2006-04-04 | Bristol-Myers Squibb Company | Parenteral formulation for epothilone analogs |
US8632788B2 (en) | 2001-01-25 | 2014-01-21 | Bristol-Myers Squibb Company | Parenteral formulation for epothilone analogs |
US6576651B2 (en) | 2001-01-25 | 2003-06-10 | Bristol-Myers Squibb Company | Pharmaceutical compositions, dosage forms and methods for oral administration of epothilones |
USRE40387E1 (en) * | 2001-01-25 | 2008-06-17 | Bristol-Myers Squibb Company | Pharmaceutical compositions, dosage forms and methods for oral administration of epothilones |
US6670384B2 (en) | 2001-01-25 | 2003-12-30 | Bristol-Myers Squibb Company | Methods of administering epothilone analogs for the treatment of cancer |
USRE41393E1 (en) | 2001-02-20 | 2010-06-22 | Bristol-Myers Squibb Company | Treatment of refractory tumors using epothilone derivatives |
US6686380B2 (en) | 2001-02-20 | 2004-02-03 | Bristol-Myers Squibb Company | Treatment of refractory tumors using epothilone derivatives |
US6727276B2 (en) | 2001-02-20 | 2004-04-27 | Bristol-Myers Squibb Company | Epothilone derivatives for the treatment of refractory tumors |
US8598215B2 (en) | 2001-03-14 | 2013-12-03 | Bristol-Myers Squibb Company | Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases |
US8569347B2 (en) | 2001-03-14 | 2013-10-29 | Bristol-Myers Squibb Company | Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases |
US7312237B2 (en) | 2001-03-14 | 2007-12-25 | Bristol-Myers Squibb Co. | Combination of epothilone analogs and chemotherapeutic agents for the treatment of prolilferative diseases |
US6800653B2 (en) | 2001-06-01 | 2004-10-05 | Bristol-Myers Squibb Compnay | Epothilone derivatives |
US7211593B2 (en) | 2002-03-12 | 2007-05-01 | Bristol-Myers Squibb Co. | C12-cyano epothilone derivatives |
US6936628B2 (en) | 2002-04-04 | 2005-08-30 | Bristol-Myers Squibb Company | Oral administration of epothilones |
US7053069B2 (en) | 2002-05-15 | 2006-05-30 | Bristol-Myers Squibb Company | Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives |
US7008936B2 (en) | 2002-06-14 | 2006-03-07 | Bristol-Myers Squibb Company | Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases |
US7759374B2 (en) | 2002-08-23 | 2010-07-20 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
US8110590B2 (en) | 2002-08-23 | 2012-02-07 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
US7875638B2 (en) | 2002-08-23 | 2011-01-25 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
US8513429B2 (en) | 2002-08-23 | 2013-08-20 | Sloan-Kettering Insitute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
US7241899B2 (en) | 2002-09-23 | 2007-07-10 | Bristol-Myers Squibb Company | Methods for the preparation, isolation and purification of epothilone B, and X-ray crystal structures of epothilone B |
USRE42191E1 (en) | 2002-09-23 | 2011-03-01 | Bristol-Myers Squibb Company | Methods for the preparation, isolation and purification of epothilone B, and X-ray crystal structures of epothilone B |
US7172884B2 (en) | 2002-09-23 | 2007-02-06 | Bristol-Myers Squibb Company | Methods for the preparation, isolation and purification of epothilone B, and x-ray crystal structures of epothilone B |
US7767432B2 (en) | 2002-09-23 | 2010-08-03 | Bristol-Myers Squibb Company | Methods for the preparation, isolation and purification of epothilone B, and x-ray crystal structures of epothilone B |
US7632858B2 (en) | 2002-11-15 | 2009-12-15 | Bristol-Myers Squibb Company | Open chain prolyl urea-related modulators of androgen receptor function |
WO2004085388A2 (en) | 2003-03-24 | 2004-10-07 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
US8871227B2 (en) | 2003-11-04 | 2014-10-28 | Bristol-Myers Squibb Company | Process and formulation containing epothilones and analogs thereof |
WO2005051947A1 (en) * | 2003-11-26 | 2005-06-09 | Leibniz-Institut Für Pflanzenbiochemie (Ipb) | Thiaepothilone for treating cancerous diseases |
US7381743B2 (en) | 2003-11-26 | 2008-06-03 | Leibniz-Institut Fuer Pflanzenbiochemie (Ipb) | Macrocycles for the treatment of cancer |
WO2005084295A2 (en) | 2004-03-01 | 2005-09-15 | Bristol-Myers Squibb Company | Fused heterotricyclic compounds as inhibitors of 17b-hydroxysteroid dehydrogenase 3 |
US8017749B2 (en) | 2006-12-04 | 2011-09-13 | The Board Of Trustees Of The University Of Illinois | Compositions and methods to treat cancer with cupredoxins and CpG rich DNA |
US9969781B2 (en) | 2006-12-04 | 2018-05-15 | Tapas Das Gupta | Compositions and methods to treat cancer with CpG rich DNA and cupredoxins |
US11046733B2 (en) | 2006-12-04 | 2021-06-29 | The Board Of Trustees Of The University Of Illinois | Compositions and methods to treat cancer with CpG rich DNA and cupredoxins |
EP2065054A1 (en) | 2007-11-29 | 2009-06-03 | Bayer Schering Pharma Aktiengesellschaft | Combinations comprising a prostaglandin and uses thereof |
EP2070521A1 (en) | 2007-12-10 | 2009-06-17 | Bayer Schering Pharma Aktiengesellschaft | Surface-modified nanoparticles |
EP2210584A1 (en) | 2009-01-27 | 2010-07-28 | Bayer Schering Pharma Aktiengesellschaft | Stable polymeric composition comprising an epothilone and an amphiphilic block copolymer |
US9138421B2 (en) | 2011-07-09 | 2015-09-22 | Beijing Fswelcome Technology Development Co., Ltd. | Platinum compounds for treating cell proliferative diseases, preparation method and use thereof |
US9175024B2 (en) | 2011-09-19 | 2015-11-03 | Beijing Fswelcome Technology Development Co., Ltd. | Platinum compound having amino or alkylamino-containing succinic acid derivatives as leaving group, preparation method thereof, and use thereof |
WO2013041014A1 (en) | 2011-09-19 | 2013-03-28 | 北京市丰硕维康技术开发有限责任公司 | Platinum compound having amino- or alkylamino-containing succinic acid derivatives as leaving group, preparation method therefor, and use thereof |
WO2014075391A1 (en) | 2012-11-17 | 2014-05-22 | 北京市丰硕维康技术开发有限责任公司 | Platinum compound of malonic acid derivative having leaving group containing amino or alkylamino |
US9725477B2 (en) | 2012-11-17 | 2017-08-08 | Beijing Fswelcome Technology Development Co., Ltd | Platinum compounds of malonic acid derivative having leaving group containing amino or alkylamino |
Also Published As
Publication number | Publication date |
---|---|
WO1993010121A1 (en) | 1993-05-27 |
DE4138042C2 (en) | 1993-10-14 |
AU2943792A (en) | 1993-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE4138042C2 (en) | Epothilones, their production processes and agents containing these compounds | |
EP1367057B1 (en) | Epothilones E and F | |
WO1998013375A1 (en) | Compounds with antimycotic and cytostatic effect, preparation method, agent containing these compounds and dsm 11 092 | |
DE3875792T2 (en) | NEW HERBICIDE, ITS PRODUCTION AND USE. | |
DE3888587T2 (en) | AB-006 antibiotics and process for their preparation. | |
EP0282455A2 (en) | Method for the preparation of a macrocyclic compound | |
EP0342363A2 (en) | Angucyclinones from streptomyces, process to obtain them and their use | |
EP0337152A1 (en) | Furans and lactones from streptomycetes, process for their preparation and their use | |
DE68924991T2 (en) | 2-pyranone derivative and process for its preparation. | |
CN108383811B (en) | Furanone derivative and extraction method and application thereof | |
DD202047A5 (en) | PROCESS FOR PREPARING THE MAKROLIDE 20-DIHYDRO-20,23-DIDEOXYTYLONOLIDE | |
DE4211056C1 (en) | Spiran heterocyclic deriv. for controlling fungi and bacteria uncontrollable - prepd. by fermenting Sorangium e.g. Polyangium cellulosum in medium contg. carbon and nitrogen sources and mineral salts in adsorber resin, and eluting | |
DE69214258T2 (en) | Antibiotic AB-041 and process for its production | |
DE19630980B4 (en) | Etnangien, production, use and production strain sorangium cellulosum DSM 11 028 | |
EP1373245B1 (en) | Intermediates for producing spinosyns | |
DE68903581T2 (en) | AGRICULTURAL SUBSTANCE AND METHOD FOR THE PRODUCTION THEREOF. | |
US5397570A (en) | Antibiotics AB-023 and process for preparing them | |
EP0339442A2 (en) | Angucyclinones from streptomyces, process to obtain them and their use | |
DE19636721A1 (en) | Antibiotic and antitumor compound, manufacturing process, agent and DSM 11 071 | |
DE69610150T2 (en) | New fungicidal compounds LL-15G256g, d and e made by LL-15G256 (Hypoxylon oceanicum) | |
DE3707955C1 (en) | Chemical compounds of the molecular formulae C29H44O8 and C28H44O8, process for their preparation and compositions containing them | |
DE3840519A1 (en) | NEW ANGUCYCLINONE FROM STREPTOMYCETES, PROCESS FOR THEIR PREPARATION AND THEIR USE | |
DE19607702A1 (en) | Heterocyclic compounds, manufacturing processes and agents | |
DE2659180C2 (en) | Antibiotic derivative of the substance SF-1540 and process for its preparation | |
DE4305486A1 (en) | Icumazoles and preparation processes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
OP8 | Request for examination as to paragraph 44 patent law | ||
D2 | Grant after examination | ||
8364 | No opposition during term of opposition | ||
R071 | Expiry of right |